RASSF1A Hypermethylation is Associated with Aflatioxin B1 and Polycyclic Aromatic Hydrocarbon Exposure in Hepatocellular Carcinoma

RASSF1A Hypermethylation is Associated with Aflatioxin B1 and Polycyclic Aromatic Hydrocarbon Exposure in Hepatocellular Carcinoma
复制标题

RASSF1A 高甲基化与肝细胞癌中黄曲霉毒素 B1 和多环芳烃暴露相关

DOI:
10.5754/hge11731
复制
发表时间:
2012-09-01
影响因子:
--
通讯作者:
Mao, Qin-Sheng
Mao, Qin-Sheng
中科院分区:
其他
文献类型:
--
作者:
Feng, Ying;Xue, Wan-Jiang;Mao, Qin-Sheng

文献摘要

被引文献

相似文献

背景/目的:在肝细胞癌(HCC)中经常观察到RASSF 1A高甲基化。但这种表观遗传学改变可能的相关危险因素和预后评估仍不清楚。方法学:检测了103例肝癌组织中RASSF 1A、黄曲霉毒素B1(AFB 1)和多环芳烃(PAH)-DNA加合物的甲基化状态、mRNA和蛋白表达。结果如下:RASSF 1A mRNA(20/103,r=-0.665)和蛋白(21/103,r=-0.761)的表达与RASSF 1A甲基化(82/103)呈负相关。多因素分析表明RASSF 1A甲基化与AFB 1-(p=0.046)和PAH-DNA加合物(p=0.040)相关。其他因素如吸烟、饮酒、B型肝炎病毒感染和临床病理参数与RASSF 1A甲基化无显著相关性。在有和没有RASSF 1A高甲基化的患者之间没有观察到总生存率的差异(p=0.267)。结论:AFB 1和PAH-DNA加合物可能与RASSF 1A甲基化有关。RASSF 1A甲基化状态可能不是肝癌总生存期的适当预测因素。
Background/Aims: RASSF1A hypermethylation is frequently observed in hepatocellular carcinomas (HCC). But the possible related risk factors and prognosis evaluation for this epigenetic alteration are still unknown. Methodology: Methylation status, mRNA and protein expression of RASSF1A, aflatoxin B1 (AFB1) and polycyclic aromatic hydrocarbon (PAH)-DNA adducts, were examined in 103 cases of HCC. Results: The expression of RASSF1A mRNA (20/103, r=-0.665) and protein (21/103, r=-0.761) were negatively related to RASSF1A hypermethylation (82/103). Multivariate analysis indicated that RASSF1A hypermethylation was related to AFB1- (p=0.046) and PAH-DNA adducts (p=0.040). Other factors including smoking, alcohol drinking, hepatitis B virus infection and clinicopathological parameters were not significantly associated with RASSF1A methylation. No difference in overall survival was observed between patients with and without RASSF1A hypermethylation (p=0.267). Conclusions: AFB1- and PAH-DNA adducts may be associated with RASSF1A hypermethylation in hepatocarcinogenesis. RASSF1A methylation status may not be a proper predictor of overall survival for HCC.